This study examined achievement of blood pressure (BP) goals, changes in antihypertensive therapy and reasons for these changes among adults with hypertension initiating angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs) or calcium channel blockers (CCBs). Claims data were examined for changes to medication regimens. Patient charts for 501 patients provided BP levels and reasons for changing medications. BP goal achievement was highest for initiators of ARBs (81.4%), compared with ACEIs (75.5%; P ¼ NS) and CCBs (68.9%; Po0.01). Changes in antihypertensive therapy were least likely among ARB recipients (59.9%) compared with ACEIs (71.86%; P ¼ 0.02) and CCBs (74.85%; Po0.01). Failure to achieve BP goals was the most common reason for change in therapy (ARB, 32.9%; ACEI, 42.5%, P ¼ NS; CCB, 47.9%, Po0.01). Although most patients achieved target BP goals, many required changes in treatment regimens. Initial choice of antihypertensive therapy may mitigate changes in therapies and better achieve BP goals.
Introduction
Hypertension is a modifiable, yet pervasive, risk factor for cardiovascular and cerebrovascular disease. 1, 2 Over the past 30 years, awareness and treatment of hypertension has increased, and this has been associated with parallel decreases in ageadjusted mortality rates from stroke and coronary heart disease. 3 Unfortunately, blood pressure (BP) goal achievement rates remain unacceptably low despite the availability of antihypertensive therapy. 3 In 2005-2006, 36% of US individuals with hypertension did not achieve target BP goals despite receiving treatment. 4 Two recent analyses of BP control within large managed care populations suggest that hypertension remains poorly controlled among these patients as well. Andrade et al. 5 conducted a medical records review of patients with an ambulatory encounter for hypertension and found that only 11% of patients were at target BP for all visits, whereas 33% of patients were not on target at any visit. In another analysis, Andros et al. 6 evaluated BP goal attainment (according to guidelines from the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure 3 ) among patients with diabetes using antihypertensives. The authors reported that only 26% of patients achieved the target BP goal; this is especially of concern, as patients with diabetes are among those at greatest risk for complications from uncontrolled hypertension.
Patients may fail to achieve BP goals for a variety of reasons; key among these are medication nonadherence and clinical inertia. A retrospective claims database analysis by Bramley et al. 7 showed the impact of adherence to antihypertensives on achievement of BP goals. Patients who were adherent to antihypertensive monotherapy, as defined by a medication possession ratio 480%, were 45% more likely to achieve BP goals than less adherent patients. Those results are consistent with a recent meta-analysis, which found that patients who adhered to their antihypertensive medication were three times more likely to achieve good BP control than those who were non-adherent. 8 Failure to achieve BP goals has also been associated with clinical inertia, that is, failure to intensify or initiate antihypertensive therapy based on evidence of failure to achieve BP goals with existing therapy. Clinical inertia as a reason for clinical failure has begun to be documented in the clinical literature for a number of chronic conditions, including hypertension. An analysis of men with hypertension at five Veterans Affairs hospitals in New England found that 40% of patients had a BPX160/90 mm Hg despite being seen by their physician more than six times per year on average. 9 The authors further reported that therapy was intensified at only 6.7% of these visits. Data based on a national online survey of hypertensive individuals conducted by Harris Interactive reported that approximately one-third of patients with elevated blood pressure did not have their medication changed or the dosage increased. 10 Justifications captured from a survey of primary care physicians from 16 countries for why clinical inertia occurs suggest that more time was needed to see a full effect after initiating a new treatment, or that seeing a clear improvement in BP was acceptable, even if the target BP level was not reached.
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Additional evidence from a study of patients of primary care providers at Veterans Affairs facilities suggested that uncertainty about whether patients' in-office blood pressure measurements represented the patients' true measurement may also explain the failure to make changes in therapy; in addition, clinical focus on non-hypertension health issues was also associated with a lower likelihood of changing antihypertensive medications. 12 Although typically considered as separate issues in hypertension management, clinical inertia and patients' medication adherence are most definitely intertwined. In patients with perceived non-adherence to antihypertensive therapy, physicians may delay intensification of therapy and instead attempt to persuade patients to be more adherent to their current regimen; Kerr et al. 12 found that one factor associated with a lower likelihood of intensifying treatment included whether the patient and provider discussed medication issues, which may in part reflect the provider's willingness to encourage improved adherence before making changes to the patient's medication regimen. Conversely, providers may misinterpret the effects of medication nonadherence as therapeutic failure and erroneously intensify the patients' medication regimen (for example, increased dose or addition of another medication), leading to patients' receipt of unnecessary medication. 13 In a recent study, Ho et al.
14 further evaluated the association of antihypertensive medication adherence and therapy intensification on BP control over time and found that in spite of therapy intensification, medication non-adherence may be the reason BP is poorly controlled in some patients. The authors reported that successful BP control was seen with the combination of intensification and adherence, suggesting that both issues must be considered when a patient is unable to achieve the BP goal. Similar findings have been reported by other investigators as well. 15 A more recent study by Rose 16 had more ambiguous findings, in which treatment intensification, measured by medication changes, was associated with decreases in systolic BP regardless of how adherent patients were to their medication regimen.
Reports currently available in the literature have identified that a number of factors other than the prescribed medications' efficacy may affect the patient's ability to control BP levels. However, effective strategies for improving the percentage of patients who achieved their goals have not been fully explored; as seen from previous studies, even regular attendance at a provider's office does not guarantee goal achievement. 9 An improved understanding of the types of changes made to patients' antihypertensive therapy and the reasoning behind those changes may help in the formulation of more effective strategies for improving control of hypertension. To address these issues, this study was conducted to examine the achievement of the BP goal, changes in antihypertensive therapy, and reasons for these changes within a managed care health plan population.
Methods

Study design
This was a retrospective analysis of health-care claims and medical records. Claims data were evaluated for hypertension diagnosis and antihypertensive medication use. Health plan members enrolled in a commercial plan or Medicare Advantage between January 2002 and June 2004 with a diagnosis of hypertension who initiated an angiotensin-converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB) or calcium channel blocker (CCB) were identified for analysis. Nurse-chart abstractors reviewed medical records to identify BP levels and evaluate reasons for medication changes.
Data sources
The administrative health-care claims database included an electronic pharmacy and medical claims and enrolment data encompassing approximately 15 million covered lives from a large US-managed care provider affiliated with i3 Innovus. The population is geographically diverse across the United States, with the majority of patients located in the South and Midwest. These data were accessed using Health Insurance Portability and Accountability Act (HIPAA)-compliant techniques, and no identifiable protected health information was extracted except where necessary and allowable under a waiver granted by the New England Institutional Review Board. Further details about the database are found elsewhere. As the study focused on patients newly initiating treatment, patients were excluded if they initiated multiple medications on the same date or had exposure to another medication that may affect BP (ACEI, ARB, CCB, b-blockers, diuretics, a-receptor blockers, a 2 adrenergic agonists or vasodilators) in the baseline period. To eliminate diagnoses recorded for rule-out reasons or white-coat hypertension, patients were required to have a primary or secondary diagnosis of hypertension (ICD-9-CM: 401.xx-405.xx) in the baseline period and the follow-up period, with at least two medical claims for hypertension on separate days. Patients were excluded if their pharmacy coverage included a cap on prescription drug benefits. Patients were also excluded from the study if they had less than a 31-day supply of ACEI, ARB or CCB over the follow-up period and had no prescription refills for another antihypertensive over the follow-up period to ensure that patients had received more than one prescription of an ACEI, ARB or CCB.
Final medical records sample and data collection. Medical records were abstracted for a target sample of 167 patients in each study cohort (total study N ¼ 501). Power calculations computed before study initiation indicated that at a ¼ 0.05, the sample size of 167 per cohort would have 480% power to detect a 15% difference in achievement of the BP goal, assuming a rate of 30 and 45% in two groups.
Random samples were identified for each cohort. If abstraction could not be completed for any reason (for example, inability to contact the provider, physician refusal), that patient was replaced by a similar patient from the pool of available subjects with abstractions continuing until the target of 167 per cohort was reached.
Following privacy board approval, protected health information and physician-specific information necessary for medical records abstraction was extracted by study staff. Medical records were abstracted by a professional medical records abstraction firm using nurses to perform the chart abstractions. Inter-rater reliability was assessed and chart abstractors were required to have a minimum of 95% concordance with a test chart (from the study sample) to participate. Medical records data collection focused on abstraction of recorded BP measurements and dates of measurements during the baseline and follow-up periods. Any indicated reasons or notations to explain changes in antihypertensive therapy were also collected. All data were de-identified before study analyses.
Study measures BP outcomes. All BP measurements were captured over the specified study follow-up period and evaluated for the percentage of patients who reached their goals over the follow-up period, time to reach BP control, and proportion of visits with controlled BP. Patients were identified as having achieved their goals if any of their follow-up measurements met the criteria suggested by JNC-7 (o140/90 mm Hg and o130/80 mm Hg for patients with diabetes). 3 The average diastolic and systolic BP levels were calculated from all measurements over the follow-up period. The time from the index date to the date of the first measurement that met the goal was calculated. For each individual, the percentage of follow-up BP measurements that achieved the goal was also calculated.
Antihypertensive medication changes. All changes to the index antihypertensive therapy over the 12-month follow-up period were identified from pharmacy claims and time to change was calculated from the index date to the date of change in medication. The specific changes identified were dose increase, dose decrease, medication discontinuation, switch to a different antihypertensive therapy, or augmentation with a different antihypertensive therapy. Medication discontinuation was defined as not receiving a prescription fill for the index medication within 60 days after exhausting the days' supply from the previous prescription. The time to discontinuation was defined as the number of days from the index date to the date of index medication supply exhaustion preceding the gap in therapy. Patients who discontinued their index medication and filled a new prescription for a different antihypertensive medication after their index date were considered to have switched medications (these patients remained classified within their index cohort for the purposes of study analyses). Patients who added an antihypertensive therapy other than their index medication and had at least one filled prescription for their index medication following the start date of the second therapy were defined as augmenting. Average daily dose was calculated on the basis of medication strength, quantity and number of days supplied on the claim, and any increase or decrease between the index prescription and subsequent prescriptions was identified. All changes to the index medication were captured over the follow-up period, as patients may have experienced a sequence of changes in their medication regimen.
Reasons for medication changes. Reasons for change in antihypertensive medication therapy were based on the data abstracted from the medical charts. The reasons included failure to achieve goal, safety/ intolerance, cost, or other factors.
Demographic and clinical characteristics. Baseline demographic and clinical characteristics were identified from administrative enrolment and claims data. Demographic characteristics focused on patient gender, age as of their index date, plan type and geographic region. Comorbidities present during the baseline period were identified from medical claims using updated methodology for classifying disease clusters as originally described by Schneeweiss et al. 18 Pharmacy claims were evaluated for concurrent medications used over the follow-up period. Medications of interest were ACEI, ARB, CCB, b-blockers, a-receptor blockers, a 2 adrenergic agonists, diuretics, digitalis, nitrates, vasodilators, combination antihypertensives, lipid-lowering medications, antiplatelet agents and antidiabetic medications. In addition, medications used over the baseline period were assessed as potential indicators of the patients' initial health status.
Statistical analyses
All data were evaluated descriptively to assess differences between ACEIs vs ARBs, ARBs vs CCBs and ACEIs vs CCBs. t-tests were adjusted assuming a Bonferonni correction of type 1 error. Chi-square tests were used to evaluate categorical data. Pairwise comparisons between the cohorts were used to identify which groups differed. Reasons for changes in antihypertensive medication recorded in medical charts during the follow-up period were also summarized descriptively.
Multivariate logistic regression models were analysed to examine the probability of achieving goals over the follow-up period. The likelihood of having any change in the index medication (based on observations within the pharmacy claims data within the follow-up period) was assessed using logistic regression models. Multivariate analyses of reasons for change (as identified in the medical records) focused on whether the patient had a reason of 'Failure to Achieve Goal' recorded.
Models were adjusted for gender, age, geographic region, index medication (that is, ACEI, ARB, CCB), number of comorbidities, baseline BP measurements, medication possession ratio for the index medication, baseline medication use and whether patients had any change in the index medication over the follow-up period. Models assessing the likelihood of change also adjusted for whether patients had achieved BP goals during the followup period.
Data extraction and statistical analyses were performed using SAS, version 8.2 (SAS Institute, Cary, NC, USA).
Results
Sample selection
Of the 1.2 million patients in the administrative claims database with a filled prescription for an ACEI, ARB or CCB between 1 January 2002 and 30 June 2004, a total of 46 714 patients were identified who met all initial patient selection criteria and were qualified for the medical chart abstraction.
The final study sample (n ¼ 501) had a slightly higher percentage of men compared with the initial claims database population (58.1 vs 56.7% male). The final study population was also slightly older than the initial claims population, with a mean (s.
Patient characteristics
Characteristics of the patients in the final chart abstraction population are included in Table 1 . The mean age of study cohorts differed slightly with the ARB cohort (50.6 years) being younger than the ACEI cohort (55.9 years; P ¼ 0.001) and the CCB cohort (59.4 years; Po0.0001). The proportion of patients with diabetes and lipid disorders before initiation of their antihypertensive therapy tended to be higher among those who received an ACEI (22.8 and 50.9%, respectively) or an ARB (18.6 and 55.1%, respectively) compared with CCB (14.4 and 43.7%, respectively), but the mean total number of comorbidities was similar for all study cohorts.
The use of concomitant medications in the baseline period was also similar between study cohorts with the exception that patients initiated on CCB were less likely to be receiving antidiabetic or lipidlowering medications, but more likely to be receiving antiplatelet medications (Table 1 ).
Blood pressure: baseline and outcomes The mean (s.d.) systolic BP measurement before the initiation of index antihypertensive therapy was 143 (13) mm Hg for both the ACEI and ARB cohorts and was higher for CCB (148 (17) mm Hg; Po0.05 vs ACEI and ARB). The mean diastolic BP at baseline was similar across all study cohorts (Table 1) .
Of the total 501 patients, 488 had a BP measurement recorded in their medical records during the study follow-up period after initiation of an antihypertensive therapy. As was observed during the baseline period, the mean (s.d.) systolic BP measurements over the follow-up period were highest for patients initiated on CCB (140 (14) mm Hg; Po0.05 for all comparisons) and were similar for ACEI and ARB cohorts (135 (13) and 133 (12) mm Hg, respectively), whereas there were no significant differences in diastolic BP across cohorts (Table 2) . Average diastolic BP measurements over the followup period were 82, 83 and 83 mm Hg for the ACEI, ARB and CCB cohorts, respectively.
More than half of the patients in each cohort achieved their BP goals (o140/90 mm Hg, and o130/80 mm Hg for patients with diabetes) on at least one occasion during follow-up. In this regard, patients initiated on ARBs were most likely to have achieved their BP goals during follow-up, with 81.4% achieving goals that were similar to the 75.5% who achieved goals when initiated on ACEIs (P-value not statistically significant) but higher than the 68.9% who reached goals with CCBs (P ¼ 0.009). The difference between the ACEI cohort and the CCB cohort was not statistically significant. Among the patients who achieved their goals, the mean time until goal achievement was 105.0, 129.0 and 127.5 days among the ACEI, ARB and CCB cohorts, respectively. Differences between the cohorts were not statistically significant.
Multivariate analysis of BP goal achievement over the study follow-up period indicated that baseline systolic BP and the use of antidiabetic medications were significantly associated with whether BP goals were achieved. With every point increase in baseline systolic BP, the odds of achieving goals were lower 
Changes in antihypertensive therapy
Overall, changes to index antihypertensive therapies identified within pharmacy claims data occurred in the majority of all patients, with 59.9% of patients initiated on ARB having changed their index antihypertensive therapy over the follow-up period compared with 71.9% of those initiated on ACEIs (P ¼ 0.02 vs ARB) and 74.9% of those initiated on CCBs (P ¼ 0.004 vs ARB; Table 3 ). The majority of patients who had a change to their index therapy had only one change (63.3, 76.0 and 72.8% of the ACEI, ARB and CCB cohorts, respectively). The proportions of patients with two changes to their index therapy during follow-up were 30.0, 24.0 and 24.0% in the ACEI, ARB and CCB cohorts, respectively. Few patients had three or more changes (6.7, 0.0 and 3.2% of ACEI, ARB and CCB cohorts, respectively). The most frequent type of change to a patient's index antihypertensive therapy was discontinuation, with 49.7, 53.3 and 52.1% of patients initiated on ACEI, ARB and CCB discontinuing (Table 3) . Increases in index dose of antihypertensive medications were also commonly noted, occurring in 17.4% of ARB subjects. Relative to patients initiated on ARBs, significantly greater proportions of ACEI subjects (31.1%; P ¼ 0.003) and CCB subjects (28.1%; P ¼ 0.02) increased the initial dose of their index medication. ARB subjects were also significantly less likely to switch therapies (Po0.0001 vs ACEI; P ¼ 0.004 vs CCB) or to augment therapy (P ¼ 0.01 vs ACEI; P ¼ 0.0002 vs CCB), although the overall number of patients (n ¼ 41) observed to have switched medications in this retrospective study was small.
Multivariate logistic regression analysis results indicated that patients receiving ARBs were significantly less likely to have a change in therapy than CCB patients (OR ¼ 0.560; 95% CI: 0.330-0.952). No other variables in the model were statistically significantly associated with changes in index antihypertensive therapy.
Reasons for change in antihypertensive therapy
Changes in antihypertensive medication were noted in medical charts for 138, 149 and 145 patients within the ACEI, ARB and CCB cohorts, respectively, over the study follow-up period (Table 4) . Among these subjects, 23.4, 50.3 and 23.4% of patients initiated on ACEI, ARB and CCB, respectively, had no identifiable reason for a change in their index medication noted within their medical chart. Discernible reasons for changes in index antihypertensive therapy were noted for 105 patients initiated on ACEIs, 74 patients initiated on ARBs and 111 patients initiated on CCBs. Among these patients, 'failure to achieve goal' was the most commonly noted reason for a change in index therapy, being present among 74.3% of the ARB cohort, 67.6% of the ACEI cohort and 72.1% of the CCB cohort. Differences between the cohorts were not statistically significant. Medication safety and/ or intolerance were also frequently noted, more so among patients who received ACEI (29.5%; P ¼ 0.001) or CCB (21.6%; P ¼ 0.03) compared with patients who received ARB (9.5%).
After adjusting for study covariates, higher baseline diastolic BP measurements were associated with higher odds of 'failure to achieve goal' as a reason for a medication change (OR ¼ 1.041; 95% CI: 1.015-1.068). Other variables evaluated through multivariate regression were not statistically significant. 
Discussion
This study used administrative health-care claims and medical records to evaluate BP goal attainment, changes to antihypertensive medication use and reasons recorded in the medical charts for changes to antihypertensive medication therapy among patients who initiated antihypertensive therapy with ACEI, ARB or CCB monotherapy. The results of the study indicate that a high proportion of patients achieved their goals in the one year following medication initiation, with some variability across the study cohorts. However, a large proportion of patients changed their antihypertensive therapy over the follow-up period, and failure to achieve goals was commonly indicated as a reason for changing therapy. Overall, the results of the analyses suggest several interesting findings. First, a large proportion of patients in this population were able to achieve their BP goals (75% across all cohorts). This is somewhat higher than what has been reported in the literature. Data from the National Health and Nutrition Examination Survey indicate that 64% of treated individuals in the United States have successfully controlled BP, 4 whereas studies of goal attainment in managed care populations have found goal achievement rates of 26-67%. [5] [6] [7] However, many of the patients in our analysis required a change in their antihypertensive therapy, such as an increase in dose or addition of a second antihypertensive medication. Thus, if patients are to achieve BP goals, physicians must be proactive in their evaluation and adjustment of patients' antihypertensive regimens, a finding supported by previous analyses. 9, 14, 19 However, the results of this study also highlight the difficulties that providers face in the gap between what providers practise in their offices and what may happen once patients leave the office. In all three cohorts, more patients had changes to their medication regimens recorded in their charts than appeared in the filled prescription claims (for example, for the ACEI cohort, 138 patients had chart-recorded changes, compared with 120 patients with claims-based changes). This gap may in part be because of the differing nature of health-care claims and medical record data; administrative claims and medical chart data reflect two semi-independent processes, neither of which was designed for the purposes of research. In addition to abstracted blood pressure data, the medical chart data captured the combination of the patients' reporting of their medication use (medical history), physician recording of prescriptions written, medications stopped or changes in medication use. As medical records data were only abstracted from a single physician's practice for each patient, data from visits to other health-care providers for an individual patient were not evaluated in this study; however, this would suggest that the chart abstraction potentially may have undercounted the changes to patients' medication regimens attempted by providers, suggesting an even wider gap between the office and the outside. As pharmacy claims reflect only the prescriptions filled, patients who did not fill prescriptions that they received, received medication samples or those who made dosage changes without requiring In this study, we also observed that patients in the ARB cohort were more likely to achieve goals over the follow-up compared with patients in the CCB cohort. This is an interesting finding, given that in this study patients initiated on ARBs had a higher percentage of patients with comorbid diabetes and therefore achieved a lower BP goal than patients taking CCB. After multivariate analysis, the difference in goal achievement between the cohorts was not statistically significant, suggesting that variations in the characteristics of the patients initiating each medication, such as the percentage of patients with diabetes, may account for differing rates of goal achievement; otherwise, it is arguable that ACEI, ARB and CCB are generally considered equivalent for the treatment of hypertension in the absence of other compelling indications.
3 ARB patients were also less likely to have a change in their therapy during follow-up. Our study suggests that ARB therapy may provide certain advantages over CCB therapy. Further study in this area is needed to examine this issue in more detail.
Another interesting observation noted in this study was that patients who received antidiabetic medications were less likely to achieve BP goals based on the multivariate analysis results. As previously noted, the cutoffs used to define the achievement of BP goals were those suggested by JNC-7. 3 Although not an explicit analysis of the study, the higher rate of patients with treated diabetes who failed to achieve their goals may in part reflect the greater difficulty in reaching the more stringent goal for this group. 6 Finally, the baseline diastolic and systolic BP measurement had differing effects on the outcomes evaluated in this study on the basis of multivariate analyses. Higher initial systolic BP levels were associated with lower odds of achieving the goal, whereas diastolic measurement had no significant impact on this outcome. However, higher initial diastolic measurement was associated with a higher likelihood of having 'failure to achieve goal' as the reason for change in the medical records, whereas systolic measurement was not statistically significant. These findings quite likely reflect the traditional focus on diastolic BP in clinical studies as the primary indicator of BP control. Despite increased evidence of the importance of systolic BP on cardiovascular end points and mortality, 3, 20 physicians appear to continue being more aggressive in their treatment of diastolic BP.
As with any study, there are some specific limitations associated with the data sources and study design. The data evaluated on the basis of administrative claims are collected for reimbursement purposes rather than research, and the claims do not include extensive clinical information, such as measures of severity of illness, blood pressure outcomes or detailed information about the clinical decision-making process. For this reason, we abstracted data from medical charts to evaluate clinical outcomes. Although the abstraction of blood pressure readings from the charts is uncomplicated, the abstraction of elements such as reasons for medication changes may have been subject to greater variation. To address this potential issue, the chart abstraction form allowed the chart abstracters to enter descriptions of any notations on reasons why the medications were changed. As part of the verification process, completed chart abstraction forms were reviewed, and all comments were manually reviewed to identify whether the reasons selected appeared consistent with the comments. These processes may have increased the consistency of the data collected; however, medical charts do not contain the same level of information available in prospective data collected concurrent with the clinical event, and therefore is a limitation of the study.
One potential confounder not included in the multivariate analyses is medication adherence; however, a descriptive analysis showed that an medication possession ratio did not differ between the cohorts. The study also did not specifically examine the impact of physician specialty on the study outcomes; however, for the initial population identified in the claims, 88% of the providers prescribing the index medication were family/general practice or internal medicine specialists.
Owing to the complexities of collecting medical record data, this study was necessarily limited in sample size for the chart abstraction. However, a high percentage of patients in each cohort achieved their goals; this may reflect in part the specific inclusion criteria required for retrospective collection of blood pressure measurement from medical charts. In particular, to assess blood pressure, both pre-and post-initiation of the antihypertensive medication, the study required that patients have visits to the same provider before and after their medication initiation; this requirement may have resulted in a study population that used health services more intensively and were potentially more closely managed for their hypertension.
Despite these limitations, we feel that this study provides important information about current antihypertensive treatment patterns for managed care patients, including how and why patients' antihypertensive regimens are changed, and how those changes affect patients' ability to achieve their BP goals.
Conclusions
Although most patients in this managed care population were able to achieve their BP goals, changes in treatment regimens were required for many of these patients. Thus, if patients are to achieve BP goals, physicians must be proactive in their evaluation and adjustment of patients' antihypertensive regimens. In addition, choice of an initial antihypertensive agent may have an impact on both the achievement of BP goals and the need to make changes to patients' antihypertensive therapy. The gap between physician practice and actual changes in filled prescriptions hints at some of the limits to physician action alone; however, the expanded use of electronic medical records, particularly those linked to pharmacy systems, offers opportunities for information 'feedback' loops that have the potential to narrow this gap and improve the real-world effectiveness of antihypertensive treatments.
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